Powerful online cancer drug discovery database unveiled

A powerful new cancer drug discovery database has been launched to speed up the process of bringing drugs from ‘bench to bedside'.

The Cancer Research UK-funded database - known as ‘canSAR' - has been set up by researchers at Cancer Research UK's Centre for Cancer Therapeutics at The Institute of Cancer Research (ICR) to create a one-stop-shop for scientists worldwide. For the first time, it brings together all the relevant biological, chemical, pharmacological and eventually clinical data about important genes and proteins in every type of cancer in a way that greatly aids the discovery of new drugs.

The freely available database allows scientists and clinicians to search through cancer-related data and information across the spectrum of research - from genomics to clinical trials - in a fraction of the time it would previously have taken them to gather this information.

Dr Bissan Al-Lazikani, an ICR scientist who led the research team that developed canSAR, said: "With the unprecedented amounts of electronic data being generated by modern molecular research techniques, the demand for a resource that brings together all this information and makes it available in a clear and manageable format is greater than ever. Previously the information was stored in many different locations and formats, which limited its effective use by researchers."

Professor Paul Workman, Director of the Cancer Research UK Centre for Cancer Therapeutics at the ICR, said: "We have already found canSAR to be fantastically useful in our own cancer drug discovery research. We are applying it to evaluate large number of potential drug targets in a faster and more systematic way than before and to select the best ones to work on. Having road tested it ourselves, I'm really excited about our powerful canSAR tool and I'm delighted to make it available to the cancer research community worldwide.

"Scientists can now, at the click of a button and at a single online location, rapidly identify the biological and structural characteristics of an actual or potential drug target, find the genes and proteins that it interacts with, assess its structural druggability and identify any small molecule chemical inhibitors. Researchers can also find information on the cancer cell lines that are most suitable for their experiments. This information is now available in minutes whereas it would previously have taken weeks to find.

"For example, one can quickly look at data on 700,000 chemical compounds acting on 4,000 molecular targets. It contains a total of more than eight million experimental data points. Patients will benefit because researchers will be able to move more quickly from a basic research discovery to new drugs in the clinic."

canSAR contains information on the entire human proteome - the protein equivalent of the human genome - as well as linking to information on more than 1,000 cancer cells lines, used by researchers to study the effect of new drugs in the lab. Importantly, scientists will also have improved access to information about all the chemical compounds known to be active on a particular drug target - linking the biology and chemistry together in a new way.

Dr Lesley Walker, Cancer Research UK's director of cancer information, said: "This new database will provide scientists with easy access to research being carried out by other specialist groups around the world, paving the way for a much more collaborative way of working.

"Hopefully this will help accelerate the pace at which discoveries involving the nuts and bolts of cancer can be translated into effective new drugs in the clinic. I'd encourage all researchers to take advantage of this important resource."

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”